Canopy Biosciences acquires Zellkraftwerk

Simultaneously closes strategic growth investment from Ampersand Capital to create a provider of genomic and cell and tissue analysis products and services

Canopy BiosciencesTM, a provider of gene editing and gene expression products and services, announced that it has acquired Zellkraftwerk, a in multiplex cytometry. Leveraging its innovative ChipCytometry platform, Zellkraftwerk offers complete workflow solutions—including both products and research services—for high-content cytometry on cells and tissues. The combination of Canopy and Zelkraftwerk creates a unique “multi-omics” company that boasts a powerful union of genomics expertise with cutting-edge cell and tissue analysis solutions to best support customers in drug development research and biomarker discovery. Concurrent with the acquisition, Canopy closed a strategic growth investment from Ampersand Capital Partners.

Edward Weinstein, Ph.D., co-founder and CEO of Canopy Biosciences, said, “I am excited to complete the transformational acquisition of Zellkraftwerk and begin our partnership with Ampersand. Ampersand’s expertise and resources will benefit Canopy as we build a broader product and service offering for our customers, and the Zellkraftwerk acquisition provides a meaningful contribution to this strategy.” Weinstein continued, “Zellkraftwerk founders Jan Detmers and Christian Hennig have built a truly differentiated offering within the cell and tissue analysis market, and we’re excited to add their unique expertise and technology platform to Canopy Biosciences.”    

Cofounder of Zellkraftwerk, Jan Detmers added, “As the scientific community continues to appreciate the roles and relationships between genotypes, phenotypes, and the environment, the need for “multi-omic” approaches to biomarker discovery and functional biology research has never been clearer. We are excited to partner with Canopy Biosciences and Ampersand to enhance our capabilities, scale, and geographic reach in the US, Europe, and Asia as we strive to best serve the evolving needs of our customers.”    

Frank Witney, Ph.D., Operating Partner at Ampersand and incoming Chairman of Canopy, said, “Ampersand invests in high quality teams who manage rapidly growing businesses with established positions in their specific markets, and Canopy is a great example. We are thrilled to have the opportunity to partner with Ed and the rest of the Canopy management team as they expand their gene editing and genomics analysis portfolio in combination with Zellkraftwerk’s unprecedented multiplex cytometry technology.

Canopy was formed in 2016 by BioGenerator, the funding arm of BioSTL in St. Louis, MO. Charlie Bolten, Senior Vice President of BioGenerator, added, “Canopy’s product portfolio is a result of a strategic approach to identify novel technologies and quickly commercialize products and services that will make an immediate impact on biomedical research. BioGenerator is proud to have played a role in the founding of this company and is excited at Canopy’s continued growth prospects in partnership with Ampersand.